Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19180861 | 1.00 | ACE (0.46) | ACEKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL19181370 | 1.00 | ACE (0.46) | ACEKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL18103844 | 1.00 | ACE (0.46) | ACEKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL19181297 | 0.92 | KLK7 (0.51) | ACEKLK7KLK5 | |
| SCHEMBL19181299 | 0.92 | KLK7 (0.51) | ACEKLK7KLK5 | |
| SCHEMBL19181972 | 0.91 | ACE (0.40) | ACE | |
| SCHEMBL19181973 | 0.91 | ACE (0.40) | ACE | |
| SCHEMBL18103807 | 0.91 | ACE (0.42) | ACEKLK7KLK5 | |
| SCHEMBL18103810 | 0.91 | ACE (0.42) | ACEKLK7KLK5 | |
| SCHEMBL19181345 | 0.87 | ACE (0.40) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062803-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2020-02-27 | — | — | US | disclosed |
| US-10246487-B2 | Azaindoline compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2019-04-02 | — | — | US | disclosed |
| US-9969772-B2 | Covalent granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2018-05-15 | — | — | US | disclosed |
| US-20170218014-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170015707-A1 | COVALENT GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2017-01-19 | — | — | US | disclosed |
| US-9458192-B1 | Covalent granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2016-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218014-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, DNASE1L3, DNASE1 | ACE 3216/4885KLK7 1326/4885KLK5 719/4885 |
| US-10246487-B2 | Azaindoline compounds as granzyme B inhibitors | GZMB, DNASE1L3, DNASE1 | ACE 3216/4885KLK7 1326/4885KLK5 719/4885 |
| US-20200062803-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, DNASE1L3, DNASE1 | ACE 3216/4885KLK7 1326/4885KLK5 719/4885 |
| US-20170015707-A1 | COVALENT GRANZYME B INHIBITORS | GZMB, CTSB, DNASE1L3 | ACE 2540/4885KLK7 1330/4885KLK5 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.